Healthcare provider profile · identity verified

Eunice Liu, D.O.

Internal Medicine · MARTINEZ, CA · NPI 1851575310

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	346	120
Amlodipine Besylate	Amlodipine Besylate	178	69
Atenolol	Atenolol	169	52
Levothyroxine Sodium	Levothyroxine Sodium	169	61
Lisinopril	Lisinopril	156	62
Losartan Potassium	Losartan Potassium	143	50
Trazodone Hcl	Trazodone Hcl	115	39
Albuterol Sulfate Hfa	Albuterol Sulfate	112	49
Furosemide	Furosemide	112	37
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	104	26
Omeprazole	Omeprazole	103	39
Metformin Hcl Er	Metformin Hcl	94	39
Fluticasone Propionate	Fluticasone Propionate	87	37
Gabapentin	Gabapentin	85	27
Simvastatin	Simvastatin	82	37
Metoprolol Tartrate	Metoprolol Tartrate	76	24
Famotidine	Famotidine	75	29
Hydrochlorothiazide	Hydrochlorothiazide	74	28
Alendronate Sodium	Alendronate Sodium	70	26
Pantoprazole Sodium	Pantoprazole Sodium	64	20
Alvesco	Ciclesonide	58	20
Tizanidine Hcl	Tizanidine Hcl	56	32
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	20
Sertraline Hcl	Sertraline Hcl	54	20
Tamsulosin Hcl	Tamsulosin Hcl	53	24
Glipizide	Glipizide	51	18
Ibuprofen	Ibuprofen	51	22
Terazosin Hcl	Terazosin Hcl	49	17
Baclofen	Baclofen	45	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	42	suppressed
Lovastatin	Lovastatin	39	15
Metoprolol Succinate	Metoprolol Succinate	39	16
Azelastine Hcl	Azelastine Hcl	35	13
Meloxicam	Meloxicam	35	15
Spiriva Respimat	Tiotropium Bromide	35	suppressed
Metformin Hcl	Metformin Hcl	34	14
Promethazine Hcl	Promethazine Hcl	34	suppressed
Allopurinol	Allopurinol	32	12
Wixela Inhub	Fluticasone Propion/Salmeterol	32	13
Montelukast Sodium	Montelukast Sodium	31	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Carvedilol	Carvedilol	29	12
Fluoxetine Hcl	Fluoxetine Hcl	29	14
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	25	11
Tramadol Hcl	Tramadol Hcl	24	suppressed
Ketoconazole	Ketoconazole	23	suppressed
Potassium Chloride	Potassium Chloride	23	11
Triamcinolone Acetonide	Triamcinolone Acetonide	23	19
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	22	suppressed
Hydrocortisone	Hydrocortisone	21	18
Acyclovir	Acyclovir	20	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	15
Humulin N	Insulin Nph Human Isophane	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Clobetasol Propionate	Clobetasol Propionate	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Jardiance	Empagliflozin	15	suppressed
Ozempic	Semaglutide	15	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Prednisone	Prednisone	14	12
Sucralfate	Sucralfate	14	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	13	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Lorazepam	Lorazepam	13	11
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Fenofibrate	Fenofibrate	12	suppressed
Finasteride	Finasteride	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error